Evidence map›Paper›PMID 23595962›Full record

ArticleJournal of physiology and biochemistry2013

Adverse cardiac responses to alpha-lipoic acid in a rat-diabetic model: possible mechanisms?

Nouf M Al-Rasheed, Nawal M Al-Rasheed, Hala A Attia, Iman H Hasan, Maha Al-Amin, Hanaa Al-Ajmi, Raeesa A Mohamad

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of physiology and biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 26 citations in OpenAlex.

  1. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Trial
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Nouf M Al-RasheedDepartment of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, 11495, Kingdom of Saudi Arabia.
Nawal M Al-Rasheed
Hala A Attia
Iman H Hasan
Maha Al-Amin
Hanaa Al-Ajmi
Raeesa A Mohamad
King Saud University · SAMansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alpha-lipoic acid (ALA) is widely used as an antioxidant for the treatment of diabetes and its complications; however, the pro-oxidant potential of ALA has recently been reported. This study was designed to investigate whether ALA supplementation could have pro-oxidant effects on cardiac tissues in normal and diabetic rats. Diabetes was induced by a single dose of streptozotocin (STZ; 55 mg/kg (intraperitoneal). Diabetic and normal rats were treated with ALA (100 mg kg(-1) day(-1)) for 45 days. ALA supplementation resulted in oxidative protein damage as evident by significant reduction in the cardiac levels of protein thiol in ALA-treated normal rats (P < 0.01) together with a significant elevation (P < 0.001) in the plasma levels of advanced oxidation protein products in ALA-treated normal rats and in ALA + STZ-diabetic rats compared with the normal control rats. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase has emerged as the major source of superoxide anion and enhanced oxidative damage in heart failure. ALA supplementation increased the myocardial immunoreactivity of p47phox subunit of NADPH oxidase in both normal nondiabetic and diabetic rats reflecting its pro-oxidant effect. Data showed that ALA supplementation failed to prevent cardiac complications in diabetic rats and led to cardiac toxicity in normal rats as indicated by pathological changes (cellular infiltration, fibrosis, and degeneration) and by the elevation of serum cardiac biomarkers compared with normal controls. The pro-oxidant effects of ALA suggest that careful selection of appropriate doses of ALA in reactive oxygen species-related diseases are critical.

Indexed as

AnimalsCholesterol, HDLCholesterol, LDLDiabetes Mellitus, ExperimentalGlycation End Products, AdvancedHeart FailureMaleMalondialdehydeMyocardiumNADPH OxidasesOxidantsRatsRats, WistarReactive Oxygen SpeciesStreptozocinThioctic AcidCholesterol, HDLCholesterol, LDLGlycation End Products, AdvancedMalondialdehydeNADPH Oxidasesneutrophil cytosolic factor 1OxidantsReactive Oxygen SpeciesStreptozocinThioctic AcidTriglyceridesTroponin IVascular Endothelial Growth Factor Avascular endothelial growth factor A, rat

Identifiers

PMID23595962
OpenAlexW2050839331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.